Skip to main content
Top

08-05-2016 | Polymyalgia rheumatica | Case report | Article

Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy

Journal: Clinical Rheumatology

Authors: Shunsuke Mori, Yukinori Koga

Publisher: Springer London

Abstract

Treatment with glucocorticoid (GC) is the preferred therapy for polymyalgia rheumatica (PMR), but some patients show poor responses to the initial GC regimen or experience flares on GC tapering. Alternative therapies for patients with GC resistance have not yet been established. To evaluate pretreatment characteristics and therapeutic outcomes of GC-resistant PMR, we followed all patients who had been diagnosed with PMR between October 2007 and February 2013, according to our standardized protocol. GC-resistant patients were defined as those who had responded poorly to the initial GC regimen (15 mg/day of prednisolone) or those who had responded to the initial regimen but had experienced a flare upon GC tapering to 5 mg/day of the maintenance dose or within the first 6 months of maintenance therapy. Out of 23 patients, nine were found to be GC-resistant cases and the others were GC responders. Baseline values of PMR activity score and its components, especially the ability to elevate the upper limbs (EUL), were significantly higher in GC-resistant patients compared with GC responders. The additional use of methotrexate (MTX, five cases), salazosulfapyridine (one case), and tocilizumab (TCZ, three cases) was effective for GC-resistant patients, although 13 to 39 weeks were required for the achievement of remission. We report the three GC-resistant cases in which TCZ was added to GC therapy with or without MTX. We also review the medical literature on the use of TCZ as of January 31, 2014 and discuss the utility of TCZ in the treatment of GC-resistant PMR.
Literature
1.
Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484–492CrossRefPubMedPubMedCentral
2.
Salvarani C, Cantini F, Macchioni P, Olivieri I, Niccoli L, Padula A et al (1998) Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 41:1221–1226CrossRefPubMed
3.
Mori S, Koga Y, Ito K (2007) Clinical characteristics of polymyalgia rheumatica in Japanese patients: evidence of synovitis and extracapsular inflammatory changes by fat suppression magnetic resonance imaging. Mod Rheumatol 17:369–375CrossRefPubMed
4.
Dasgupta B, Borg FA, Hassan N, Barraclough K, Bourke B, Fulcher J et al (2010) BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology (Oxford) 49:186–190CrossRef
5.
Salvarani C, Cantini F, Niccoli L, Macchioni P, Consonni D, Bajocchi G et al (2005) Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 53:33–38CrossRefPubMed
6.
Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE (2005) Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32:65–73PubMed
7.
Pulsatelli L, Boiardi L, Pignotti E, Dolzani P, Silvestri T, Macchioni P et al (2008) Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum 59:1147–1154CrossRefPubMed
8.
Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG (1997) Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40:1873–1878CrossRefPubMed
9.
Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B et al (2007) Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 57:803–809CrossRefPubMed
10.
Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH (1979) An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38:434–439CrossRefPubMedPubMedCentral
11.
Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 48:658–661CrossRefPubMedPubMedCentral
12.
Kyle V, Hazleman BL (1989) Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 48:662–666CrossRefPubMedPubMedCentral
13.
Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA (2007) The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 57:810–815CrossRefPubMed
14.
Leeb BF, Bird HA (2004) A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 63:1279–1283CrossRefPubMedPubMedCentral
15.
Hagihara K, Kawase I, Tanaka T, Kishimoto T (2010) Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 37:1075–1076CrossRefPubMed
16.
Christidis D, Jain S, Das Gupta B (2011) Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep
17.
Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156PubMed
18.
Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B et al (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720–1729CrossRefPubMed
19.
Ashraf FA, Anjum S, Hussaini A, Fraser A (2013) Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta. BMJ Case Rep
20.
Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R et al (2013) Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 43:113–118CrossRefPubMed
21.
Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A (2013) Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 19:400–401CrossRefPubMed
22.
Dasgupta B, Panayi GS (1990) Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 29:456–458CrossRefPubMed
23.
Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM (1993) Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 36:1286–1294CrossRefPubMed
24.
Corrigall VM, Dolan AL, Dasgupta B, Panayi GS (1997) The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol 36:976–980CrossRefPubMed
25.
Uddhammar A, Sundqvist KG, Ellis B, Rantapaa-Dahlqvist S (1998) Cytokines and adhesion molecules in patients with polymyalgia rheumatica. Br J Rheumatol 37:766–769CrossRefPubMed
26.
Straub RH, Gluck T, Cutolo M, Georgi J, Helmke K, Scholmerich J et al (2000) The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology (Oxford) 39:624–631CrossRef
27.
Cutolo M, Straub RH, Foppiani L, Prete C, Pulsatelli L, Sulli A et al (2002) Adrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol 29:748–756PubMed
28.
Cutolo M, Montecucco CM, Cavagna L, Caporali R, Capellino S, Montagna P et al (2006) Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 65:1438–1443CrossRefPubMedPubMedCentral
29.
Alvarez-Rodriguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R et al (2010) Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 69:263–269CrossRefPubMed
30.
Caplanne D, Le Parc JM, Alexandre JA (1996) Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 55:403–404CrossRefPubMedPubMedCentral
31.
Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ (1999) Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159:577–584CrossRefPubMed
32.
Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M (2008) Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 44:207–220CrossRefPubMed
33.
Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493–500CrossRefPubMed
34.
Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C et al (2008) Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol 26:395–400PubMed
35.
van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis 55:218–223CrossRefPubMedPubMedCentral
36.
Cimmino MA, Parodi M, Caporali R, Montecucco C (2006) Is the course of steroid-treated polymyalgia rheumatica more severe in women? Ann N Y Acad Sci 1069:315–321CrossRefPubMed
37.
Lee JH, Choi ST, Kim JS, Yoon BY, Kwok SK, Kim HS et al (2013) Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int 33:1475–1480CrossRefPubMed
38.
Narvaez J, Nolla-Sole JM, Clavaguera MT, Valverde-Garcia J, Roig-Escofet D (1999) Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis. J Rheumatol 26:1945–1952PubMed
39.
Schreiber S, Buyse M (1995) The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol 14:315–318CrossRefPubMed
40.
Cantini F, Salvarani C, Olivieri I, Macchioni L, Ranzi A, Niccoli L et al (2000) Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30:17–24CrossRefPubMed
41.
Behn AR, Perera T, Myles AB (1983) Polymyalgia rheumatica and corticosteroids: how much for how long? Ann Rheum Dis 42:374–378CrossRefPubMedPubMedCentral
42.
Kyle V, Hazleman BL (1993) The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment. Ann Rheum Dis 52:847–850CrossRefPubMedPubMedCentral
43.
Ayoub WT, Franklin CM, Torretti D (1985) Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med 79:309–315CrossRefPubMed
44.
Cimmino MA, Parodi M, Montecucco C, Caporali R (2011) The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskelet Disord 12:94CrossRefPubMedPubMedCentral
45.
Leeb BF, Bird HA, Nesher G, Andel I, Hueber W, Logar D et al (2003) EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT). Ann Rheum Dis 62:1189–1194CrossRefPubMedPubMedCentral
46.
Binard A, de Bandt M, Berthelot JM, Saraux A, Inflammatory Joint Disease Working Group of the French Society for R (2008) Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum 59:263–269CrossRefPubMed
47.
Binard A, De Bandt M, Berthelot JM, Saraux A, Inflammatory Joint Disease Working Group CRIotFSfR (2007) Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: a study of 243 scenarios. Arthritis Rheum 57:481–486CrossRefPubMed